Evidence map›Paper›PMID 33152197›Full record

ArticleBiomedica : revista del Instituto Nacional de Salud2020

Performance of rapid IgM-IgG combined antibody tests in the occupational surveillance of COVID-19 in Colombian enterprises

Álvaro J Idrovo, José Moreno-Montoya, Carlos E Pinzón-Flórez

Abstract read
In one paragraph

Article in Biomedica : revista del Instituto Nacional de Salud, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Álvaro J IdrovoDepartamento de Salud Pública, Escuela de Medicina, Universidad Industrial de Santander, Bucaramanga, Colombia. idrovoaj@yahoo.com.mx.
José Moreno-MontoyaSubdirección de Estudios Clínicos, Fundación Santa Fe de Bogotá, Bogotá D.C, Colombia. biomedica@ins.gov.co.
Carlos E Pinzón-FlórezSubgerencia de Medicamentos, EPS Sanitas, Bogotá D.C, Colombia. biomedica@ins.gov.co.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rapid IgM-IgG combined antibody tests can play an important role in the COVID-19 surveillance by supporting the diagnosis of infection, assessing the immune response, and verifying the progress towards herd immunity. Objective: To evaluate the performance of rapid IgM-IgG combined antibody tests in COVID-19 occupational surveillance in a group of Colombian enterprises. Materials and methods: We used the occupational surveillance data from companies that had performed periodic serological tests on all personnel from the end of April to the beginning of July, 2020. Workers were organized in small groups (“social bubbles”) to prevent outbreaks and optimize surveillance. The sensitivity was estimated as if the sampling had a prospective design. We describe here the changes in serological testing through periodic rounds. Results: Data were obtained from 4,740 workers, of whom only 23 were symptomatic showing changes from IgM(-)/IgG(-) to IgM(+) and then to IgM(+)/IgG(+) and IgG(+). The sensitivity was 40.94% for IgM(+) and 47.95% for IgM(+)/IgG(+). This implies that a little less than half of the cases can be detected. Conclusion: Antibody rapid tests have a role in the diagnostic process of infection and they must be evaluated taking into account the moment of the epidemic, the type of test purchased, and the populations at risk since their results depend on the number of infections and cases. In the context of a health crisis, they can be optimized by organizing workers into “social bubbles”

Indexed as

Clinical Laboratory TechniquesPandemicsAdultAntibodies, ViralAsymptomatic InfectionsBetacoronavirusColombiaCommerceCoronavirus InfectionsCOVID-19COVID-19 TestingFemaleHumansImmunoglobulin GImmunoglobulin MInterpersonal RelationsAntibodies, ViralImmunoglobulin GImmunoglobulin MCoronavirus infectionsepidemicsimmunityoccupational health

Identifiers

PMID33152197
PMCPMC7676829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.